The HER2 signaling pathway, among others, is a major driver of tumor cell proliferation and survival in this breast cancer subtype, and an effective therapeutic target of the monoclonal antibody trastuzumab [55,56]. This evidence concerns the gene ERBB2 and breast cancer.